Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes.

Simeone PG, Costantino S, Liani R, Tripaldi R, Di Castelnuovo A, Tartaro A, Mengozzi A, Cosentino F, Cipollone F, Consoli A, Paneni F, Santilli F

Cardiovascular diabetology13 Jun 2025Cited by 9 (Europe PMC)

PMID40514652PMCIDPMC12164075DOI10.1186/s12933-025-02706-8PepBankPUB-40514652

Read at source PubMedAsk about this study

Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study16

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In people with obesity and prediabetes or newly diagnosed T2D, IL-1β-expression reductions did not differ between liraglutide and lifestyle groups after comparable weight loss (P for difference=0.56); no numerical native contrast was reported.
In plain wordsIn obesity with prediabetes/new T2D, IL-1β reductions showed no significant difference between liraglutide and lifestyle groups after comparable weight loss.
Peptide
Liraglutide
Outcome
No significant changeIL-1β expression
Study
n = 32
Comparator
lifestyle counselling
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Measurements
Between-group P-value
0.56
IL-1β-expression reduction after comparable weight loss
Source sentences
Summary
After achievement of the weight loss target in the two groups, a significant but comparable reduction of IL-1β (p for difference = 0.56) was observed in both arms, in parallel with a comparable improvement in glycaemic control, C reactive protein (CRP), BMI and MASLD.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
Report a problemFND-4051465201
02HumanRandomized controlled trialEfficacy outcome
In people with obesity and prediabetes or newly diagnosed T2D, liraglutide and lifestyle groups had comparable glycemic control improvements after comparable weight loss; no signed coefficient, endpoint-specific test or native superiority was reported.
In plain wordsIn obesity with prediabetes/new T2D, liraglutide and lifestyle groups had comparable blood-sugar control improvements after weight loss; the signed effect and test were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedGlycaemic control
Study
n = 32
Comparator
lifestyle counselling
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
After achievement of the weight loss target in the two groups, a significant but comparable reduction of IL-1β (p for difference = 0.56) was observed in both arms, in parallel with a comparable improvement in glycaemic control, C reactive protein (CRP), BMI and MASLD.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
Report a problemFND-4051465202
03HumanRandomized controlled trialEfficacy outcome
In people with obesity and prediabetes or newly diagnosed T2D, liraglutide and lifestyle groups had comparable C-reactive protein improvements after comparable weight loss; no signed coefficient, endpoint-specific test or native superiority was reported.
In plain wordsIn obesity with prediabetes/new T2D, liraglutide and lifestyle groups had comparable C-reactive protein improvements after weight loss; the signed effect and test were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedC-reactive protein
Study
n = 32
Comparator
lifestyle counselling
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
After achievement of the weight loss target in the two groups, a significant but comparable reduction of IL-1β (p for difference = 0.56) was observed in both arms, in parallel with a comparable improvement in glycaemic control, C reactive protein (CRP), BMI and MASLD.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
Report a problemFND-4051465203
04HumanRandomized controlled trialEfficacy outcome
In people with obesity and prediabetes or newly diagnosed T2D, liraglutide and lifestyle groups had comparable BMI improvements after comparable weight loss; no signed coefficient, endpoint-specific test or native superiority was reported.
In plain wordsIn obesity with prediabetes/new T2D, liraglutide and lifestyle groups had comparable BMI improvements after weight loss; the signed effect and test were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedBody mass index
Study
n = 32
Comparator
lifestyle counselling
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Source sentences
Summary
After achievement of the weight loss target in the two groups, a significant but comparable reduction of IL-1β (p for difference = 0.56) was observed in both arms, in parallel with a comparable improvement in glycaemic control, C reactive protein (CRP), BMI and MASLD.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
Report a problemFND-4051465204
05HumanRandomized controlled trialEfficacy outcome
In people with obesity and prediabetes or newly diagnosed T2D, liraglutide and lifestyle groups had comparable MASLD extent improvements after comparable weight loss; no signed coefficient, endpoint-specific test or native superiority was reported.
In plain wordsIn obesity with prediabetes/new T2D, liraglutide and lifestyle groups had comparable fatty-liver disease improvements after weight loss; the signed effect and test were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedMetabolic dysfunction-associated steatotic liver disease extent
Study
n = 32
Comparator
lifestyle counselling
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
After achievement of the weight loss target in the two groups, a significant but comparable reduction of IL-1β (p for difference = 0.56) was observed in both arms, in parallel with a comparable improvement in glycaemic control, C reactive protein (CRP), BMI and MASLD.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
Report a problemFND-4051465205
06HumanRandomized controlled trialEfficacy outcome
In people with obesity and prediabetes or newly diagnosed T2D, IL-1β expression decreased in the liraglutide arm after the weight-loss target, as in the lifestyle arm; the native coefficient, within-arm test and analyzed N were unstated.
In plain wordsIn obesity with prediabetes/new T2D, IL-1β decreased after weight loss in the liraglutide arm, as in the lifestyle arm; native estimates were unstated.
Peptide
Liraglutide
Outcome
DecreaseIL-1β-expression reduction within liraglutide arm
Study
n: not reported in source
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated
Source sentences
Summary
After achievement of the weight loss target in the two groups, a significant but comparable reduction of IL-1β (p for difference = 0.56) was observed in both arms, in parallel with a comparable improvement in glycaemic control, C reactive protein (CRP), BMI and MASLD.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
Report a problemFND-4051465206

Studies that did not test the peptide alone10

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

07HumanNot a test of Liraglutide aloneObservational studyOther
Before treatment in the liraglutide/lifestyle study of people with obesity and prediabetes or newly diagnosed T2D, baseline IL-1β was positively correlated with BMI; no native drug effect or correlation coefficient was reported.
In plain wordsBefore treatment in obesity/prediabetes-or-T2D cohorts, higher IL-1β was linked to higher BMI; no native drug effect was reported.
Peptide
Liraglutide
Outcome
IncreaseBaseline IL-1β positive correlation with BMI
Study
n = 32
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
At baseline, IL-1β was positively correlated to body mass index (BMI), fasting plasma glucose, HbA1c, VAT, MASLD extent, platelet count, chemerin and interleukin-1 receptor antagonist (IL1-RA).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4051465207
08HumanNot a test of Liraglutide aloneObservational studyOther
Before treatment in the liraglutide/lifestyle study of people with obesity and prediabetes or newly diagnosed T2D, baseline IL-1β was positively correlated with fasting plasma glucose; no native drug effect or correlation coefficient was reported.
In plain wordsBefore treatment in obesity/prediabetes-or-T2D cohorts, higher IL-1β was linked to higher fasting plasma glucose; no native drug effect was reported.
Peptide
Liraglutide
Outcome
IncreaseBaseline IL-1β positive correlation with fasting plasma glucose
Study
n = 32
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
At baseline, IL-1β was positively correlated to body mass index (BMI), fasting plasma glucose, HbA1c, VAT, MASLD extent, platelet count, chemerin and interleukin-1 receptor antagonist (IL1-RA).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4051465208
09HumanNot a test of Liraglutide aloneObservational studyOther
Before treatment in the liraglutide/lifestyle study of people with obesity and prediabetes or newly diagnosed T2D, baseline IL-1β was positively correlated with HbA1c; no native drug effect or correlation coefficient was reported.
In plain wordsBefore treatment in obesity/prediabetes-or-T2D cohorts, higher IL-1β was linked to higher HbA1c; no native drug effect was reported.
Peptide
Liraglutide
Outcome
IncreaseBaseline IL-1β positive correlation with HbA1c
Study
n = 32
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
At baseline, IL-1β was positively correlated to body mass index (BMI), fasting plasma glucose, HbA1c, VAT, MASLD extent, platelet count, chemerin and interleukin-1 receptor antagonist (IL1-RA).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4051465209
10HumanNot a test of Liraglutide aloneObservational studyOther
Before treatment in the liraglutide/lifestyle study of people with obesity and prediabetes or newly diagnosed T2D, baseline IL-1β was positively correlated with visceral adipose tissue; no native drug effect or correlation coefficient was reported.
In plain wordsBefore treatment in obesity/prediabetes-or-T2D cohorts, higher IL-1β was linked to higher visceral adipose tissue; no native drug effect was reported.
Peptide
Liraglutide
Outcome
IncreaseBaseline IL-1β positive correlation with visceral adipose tissue
Study
n = 32
Outcome group
Body composition · Metabolic and weight
Source sentences
Summary
At baseline, IL-1β was positively correlated to body mass index (BMI), fasting plasma glucose, HbA1c, VAT, MASLD extent, platelet count, chemerin and interleukin-1 receptor antagonist (IL1-RA).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4051465210
11HumanNot a test of Liraglutide aloneObservational studyOther
Before treatment in the liraglutide/lifestyle study of people with obesity and prediabetes or newly diagnosed T2D, baseline IL-1β was positively correlated with MASLD extent; no native drug effect or correlation coefficient was reported.
In plain wordsBefore treatment in obesity/prediabetes-or-T2D cohorts, higher IL-1β was linked to higher MASLD extent; no native drug effect was reported.
Peptide
Liraglutide
Outcome
IncreaseBaseline IL-1β positive correlation with MASLD extent
Study
n = 32
Outcome group
Liver fat and liver function · Liver
Source sentences
Summary
At baseline, IL-1β was positively correlated to body mass index (BMI), fasting plasma glucose, HbA1c, VAT, MASLD extent, platelet count, chemerin and interleukin-1 receptor antagonist (IL1-RA).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4051465211
12HumanNot a test of Liraglutide aloneObservational studyOther
Before treatment in the liraglutide/lifestyle study of people with obesity and prediabetes or newly diagnosed T2D, baseline IL-1β was positively correlated with platelet count; no native drug effect or correlation coefficient was reported.
In plain wordsBefore treatment in obesity/prediabetes-or-T2D cohorts, higher IL-1β was linked to higher platelet count; no native drug effect was reported.
Peptide
Liraglutide
Outcome
IncreaseBaseline IL-1β positive correlation with platelet count
Study
n = 32
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
At baseline, IL-1β was positively correlated to body mass index (BMI), fasting plasma glucose, HbA1c, VAT, MASLD extent, platelet count, chemerin and interleukin-1 receptor antagonist (IL1-RA).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4051465212
13HumanNot a test of Liraglutide aloneObservational studyOther
Before treatment in the liraglutide/lifestyle study of people with obesity and prediabetes or newly diagnosed T2D, baseline IL-1β was positively correlated with chemerin; no native drug effect or correlation coefficient was reported.
In plain wordsBefore treatment in obesity/prediabetes-or-T2D cohorts, higher IL-1β was linked to higher chemerin; no native drug effect was reported.
Peptide
Liraglutide
Outcome
IncreaseBaseline IL-1β positive correlation with chemerin
Study
n = 32
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
At baseline, IL-1β was positively correlated to body mass index (BMI), fasting plasma glucose, HbA1c, VAT, MASLD extent, platelet count, chemerin and interleukin-1 receptor antagonist (IL1-RA).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4051465213
14HumanNot a test of Liraglutide aloneObservational studyOther
Before treatment in the liraglutide/lifestyle study of people with obesity and prediabetes or newly diagnosed T2D, baseline IL-1β was positively correlated with interleukin-1 receptor antagonist; no native drug effect or correlation coefficient was reported.
In plain wordsBefore treatment in obesity/prediabetes-or-T2D cohorts, higher IL-1β was linked to higher interleukin-1 receptor antagonist; no native drug effect was reported.
Peptide
Liraglutide
Outcome
IncreaseBaseline IL-1β positive correlation with interleukin-1 receptor antagonist
Study
n = 32
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
At baseline, IL-1β was positively correlated to body mass index (BMI), fasting plasma glucose, HbA1c, VAT, MASLD extent, platelet count, chemerin and interleukin-1 receptor antagonist (IL1-RA).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4051465214
15HumanNot a test of Liraglutide aloneObservational studyOther
In pooled liraglutide/lifestyle cohorts of people with obesity and prediabetes or newly diagnosed T2D, baseline IL-1β independently predicted MASLD-decrease extent (P=0.030); the predictor coefficient, exact continuous reference and native-drug effect were unstated.
In plain wordsIn obesity with prediabetes/new T2D, baseline IL-1β predicted fatty-liver improvement across liraglutide/lifestyle cohorts; no native drug effect was reported.
Peptide
Liraglutide
Outcome
Direction not reportedBaseline IL-1β independent prediction of MASLD decrease
Study
n: not reported in source
Outcome group
Liver fat and liver function · Liver
Measurements
Predictor P-value
0.03
independent baseline IL-1β prediction, not an explicit pairwise tertile test
Source sentences
Summary
Furthermore, basal IL-1β levels independently predicted the extent of MASLD decrease (p = 0.030); subjects in the highest tertile showed a median decrease of - 8.0 (95% CI - 12.3 to - 4.8) compared with - 23.0 (95% CI - 39.5 to - 16.3) in the lowest tertile.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4051465215
16HumanNot a test of Liraglutide aloneObservational studyOther
In pooled liraglutide/lifestyle cohorts of people with obesity and prediabetes or newly diagnosed T2D, the highest baseline IL-1β tertile had smaller MASLD-decrease magnitude (printed median -8.0,95% CI -12.3 to-4.8) than the lowest (median -23.0,CI -39.5 to-16.3); units and analyzed subset N were unstated.
In plain wordsIn obesity with prediabetes/new T2D, the highest baseline IL-1β tertile showed less fatty-liver improvement than the lowest across pooled liraglutide/lifestyle groups.
Peptide
Liraglutide
Outcome
DecreaseMASLD-decrease magnitude in highest versus lowest baseline IL-1β tertile
Study
n: not reported in source
Comparator
Lowest baseline IL-1β tertile
Outcome group
Liver fat and liver function · Liver
Measurements
Highest-tertile median decrease
−8
as printed; native-drug estimate and units unstated
Highest-tertile95% CI
−12.3 to −4.8
median decrease
Lowest-tertile median decrease
−23
as printed
Lowest-tertile95% CI
−39.5 to −16.3
median decrease
Source sentences
Summary
Furthermore, basal IL-1β levels independently predicted the extent of MASLD decrease (p = 0.030); subjects in the highest tertile showed a median decrease of - 8.0 (95% CI - 12.3 to - 4.8) compared with - 23.0 (95% CI - 39.5 to - 16.3) in the lowest tertile.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty-two obese subjects with prediabetes (n = 16) or newly diagnosed T2D (n = 16), were randomized to the glucagon-like peptide receptor agonist (GLP1-RA) liraglutide or lifestyle counselling until achieving a comparable weight loss.
Summary · context
Visceral adipose tissue (VAT) and gene expression of IL-1β in peripheral blood mononuclear cells were assessed by magnetic resonance and real time PCR, respectively.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4051465216

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Interleukin-1β in circulating mononuclear cells predicts steatotic liver disease improvement after weight loss in subjects with obesity and prediabetes or type 2 diabetes.

Summary

Results from this study16

Studies that did not test the peptide alone10

Version history

Subjects

Publication types

MeSH terms

Keywords